154 related articles for article (PubMed ID: 24900349)
21. Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol.
Zhu W; Chen Z; Li Q; Tan G; Hu G
Curr Med Chem; 2016; 23(6):623-33. PubMed ID: 26795197
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ulmschneider S; Müller-Vieira U; Klein CD; Antes I; Lengauer T; Hartmann RW
J Med Chem; 2005 Mar; 48(5):1563-75. PubMed ID: 15743198
[TBL] [Abstract][Full Text] [Related]
23. Steroid 11-beta-hydroxylase deficiency caused by compound heterozygosity for a novel mutation, p.G314R, in one CYP11B1 allele, and a chimeric CYP11B2/CYP11B1 in the other allele.
Kuribayashi I; Nomoto S; Massa G; Oostdijk W; Wit JM; Wolffenbuttel BH; Shizuta Y; Honke K
Horm Res; 2005; 63(6):284-93. PubMed ID: 16024935
[TBL] [Abstract][Full Text] [Related]
24. Increased ratio of mRNA expression of the genes CYP17 and CYP11B1 indicates autonomous cortisol production in adrenocortical tumors.
Enberg U; Hennings J; Volpe C; Hellman P; Höög A; Hamberger B; Thorén M
J Endocrinol Invest; 2009 Nov; 32(10):810-5. PubMed ID: 19564722
[TBL] [Abstract][Full Text] [Related]
25. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors.
Engelhardt D; Weber MM
J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):261-7. PubMed ID: 8043488
[TBL] [Abstract][Full Text] [Related]
26. Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.
Yin L; Hu Q; Emmerich J; Lo MM; Metzger E; Ali A; Hartmann RW
J Med Chem; 2014 Jun; 57(12):5179-89. PubMed ID: 24899257
[TBL] [Abstract][Full Text] [Related]
27. The potential of targeting CYP11B.
Bernhardt R
Expert Opin Ther Targets; 2016 Aug; 20(8):923-34. PubMed ID: 26854589
[TBL] [Abstract][Full Text] [Related]
28. Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer.
Hu Q; Yin L; Hartmann RW
J Med Chem; 2012 Aug; 55(16):7080-9. PubMed ID: 22861193
[TBL] [Abstract][Full Text] [Related]
29. Disorders of the aldosterone synthase and steroid 11beta-hydroxylase deficiencies.
Peter M; Dubuis JM; Sippell WG
Horm Res; 1999; 51(5):211-22. PubMed ID: 10559665
[TBL] [Abstract][Full Text] [Related]
30. Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome P450 inhibition: a patent evaluation WO2015048311 (A1).
Schroeder RL; Tram P; Liu J; Foroozesh M; Sridhar J
Expert Opin Ther Pat; 2016; 26(1):139-47. PubMed ID: 26514241
[TBL] [Abstract][Full Text] [Related]
31. Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.
Grombein CM; Hu Q; Rau S; Zimmer C; Hartmann RW
Eur J Med Chem; 2015 Jan; 90():788-96. PubMed ID: 25528333
[TBL] [Abstract][Full Text] [Related]
32. Osilodrostat: 11β-hydroxylase inhibitor for treatment of Cushing's disease.
Paton DP
Drugs Today (Barc); 2020 Oct; 56(10):643-654. PubMed ID: 33185629
[TBL] [Abstract][Full Text] [Related]
33. Potent 11β-hydroxylase inhibitors with inverse metabolic stability in human plasma and hepatic S9 fractions to promote wound healing.
Zhu W; Hu Q; Hanke N; van Koppen CJ; Hartmann RW
J Med Chem; 2014 Sep; 57(18):7811-7. PubMed ID: 25176013
[TBL] [Abstract][Full Text] [Related]
34. The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors.
Müller-Vieira U; Angotti M; Hartmann RW
J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):259-70. PubMed ID: 15985365
[TBL] [Abstract][Full Text] [Related]
35. A steady state system for in vitro evaluation of steroidogenic pathway dynamics: Application for CYP11B1, CYP11B2 and CYP17 inhibitors.
Mangelis A; Jühlen R; Dieterich P; Peitzsch M; Lenders JWM; Hahner S; Schirbel A; Eisenhofer G
J Steroid Biochem Mol Biol; 2019 Apr; 188():38-47. PubMed ID: 30529282
[TBL] [Abstract][Full Text] [Related]
36. Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors.
Papillon JP; Adams CM; Hu QY; Lou C; Singh AK; Zhang C; Carvalho J; Rajan S; Amaral A; Beil ME; Fu F; Gangl E; Hu CW; Jeng AY; LaSala D; Liang G; Logman M; Maniara WM; Rigel DF; Smith SA; Ksander GM
J Med Chem; 2015 Jun; 58(11):4749-70. PubMed ID: 25953419
[TBL] [Abstract][Full Text] [Related]
37. Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors.
LaSala D; Shibanaka Y; Jeng AY
Anal Biochem; 2009 Nov; 394(1):56-61. PubMed ID: 19622340
[TBL] [Abstract][Full Text] [Related]
38. Functional maturation of the primate fetal adrenal in vivo: 3. Specific zonal localization and developmental regulation of CYP21A2 (P450c21) and CYP11B1/CYP11B2 (P450c11/aldosterone synthase) lead to integrated concept of zonal and temporal steroid biosynthesis.
Coulter CL; Jaffe RB
Endocrinology; 1998 Dec; 139(12):5144-50. PubMed ID: 9832454
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of CYP17 and CYP11B1 in subclinical Cushing's syndrome due to adrenal adenomas.
Cao C; Yang X; Li L; Sun R; Xian Y; Lv W; Wang J; Xu Y; Gao Y
Int J Urol; 2011 Oct; 18(10):691-6. PubMed ID: 21848792
[TBL] [Abstract][Full Text] [Related]
40. Highly potent and selective nonsteroidal dual inhibitors of CYP17/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases.
Pinto-Bazurco Mendieta MA; Hu Q; Engel M; Hartmann RW
J Med Chem; 2013 Aug; 56(15):6101-7. PubMed ID: 23859149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
